Table 2. . Phase III trial efficacy and safety results of pembrolizumab, nivolumab and ipilimumab.

Drug(s)	Response rate (RECIST)	Median PFS (months)	Median OS (months)	Toxicity	Ref.
Pembrolizumab (ipilimumab-naive)	33%†	4.8†	Not reached; 12-month OS 71%	Fatigue, diarrhea, rash, pruritus	[16]
Nivolumab (ipilimumab-treated)	32%	4.7	Not reported	Fatigue, pruritus, diarrhea, nausea	[21]
Nivolumab (first-line)	40%	5.1	Not reached; 12-month OS 73%	Fatigue, pruritus, nausea, diarrhea	[20]
Ipilimumab + dacarbazine	15%	3.0	11.2	Pyrexia, diarrhea, increased hepatic transaminases, pruritus	[24]
Ipilimumab + Gp100 vaccine	11%	2.8	10	Diarrhea, nausea, fatigue, skin toxicity	[23]
Ipilimumab + nivolumab	58%	11.5	Not reported	Diarrhea, fatigue, pruritus, rash	[15]

^†Mean value of the two dose cohorts of pembrolizumab (2 mg/kg 2 and 3 weekly).

OS: Overall survival; PFS: Progression-free survival; RECIST: Response evaluation criteria in solid tumors.